What is Prime Medicine's restricted cash?

Prime Medicine (PRME) reported restricted cash of $13.69M in Q1 2026.

How has Prime Medicine's restricted cash changed year-over-year?

Prime Medicine's restricted cash decreased by 2.6% year-over-year, from $14.06M to $13.69M.

What is the long-term trend for Prime Medicine's restricted cash?

Over 4 years (2021 to 2025), Prime Medicine's restricted cash has grown at a 1.1% compound annual growth rate (CAGR), from $13.13M to $13.69M.

What does restricted cash mean?

Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.

Prime Medicine PRME Restricted Cash

Restricted Cash at other companies

CRISPR TherapeuticsCRSP

$7.63M-4.7%

Beam TherapeuticsBEAM

$6.69M+1.3%

RegenxbioRGNX

$2.03M0.0%

Sana BiotechnologySANA

$4.2M0.0%

MeiraGTx Holdings plcMGTX

$2.22M+6.2%

Vertex PharmaceuticalsVRTX

——

Other financials

Income statement

See full

Revenue$838.0K-61.6%

Operating income-$50.7M+3.3%

Net income-$49.1M+5.3%

EPS (diluted)-$0.28+30.0%

Balance sheet

See full

Cash & equivalents$77.8M-26.6%

Total debt$114.5M-5.5%

Total equity$76.7M-28.3%

Total assets$294.7M-10.2%

Cash flow

See full

Operating cash flow-$42.7M+12.6%

CapEx$214.0K-91.2%

Free cash flow-$42.9M+16.3%

Valuation

See full

Market cap$574.36M+111%

Enterprise value$611.08M+113%

P/S124×+6.3×

Profitability

See full

Operating margin-4,498.1%-1,134pp

Net margin-4,342.4%-1,099pp

FCF margin-3,607.4%—

Returns & leverage

See full

Return on equity-216.1%+1,519pp

Debt / equity1.5×+0.4×

Current ratio3.8×-1.0×

Where this comes from

Reported directly by Prime Medicine in its filing.

Tagged under the XBRL concept us-gaap:RestrictedCash.

The official record: Prime Medicine’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Prime Medicine's restricted cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Prime Medicine's restricted cash?: Prime Medicine (PRME) reported restricted cash of $13.69M in Q1 2026.
How has Prime Medicine's restricted cash changed year-over-year?: Prime Medicine's restricted cash decreased by 2.6% year-over-year, from $14.06M to $13.69M.
What is the long-term trend for Prime Medicine's restricted cash?: Over 4 years (2021 to 2025), Prime Medicine's restricted cash has grown at a 1.1% compound annual growth rate (CAGR), from $13.13M to $13.69M.
What does restricted cash mean?: Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.